
CLAIMS

What is claimed is:


1. A compound of formula (**I**):



(**I**)


or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or stereoisomer thereof,




wherein Z is



and wherein


R_1 is hydrogen, cycloalkyl, aryl, or C_1-C_3 alkylaryl, each of which is optionally substituted by one or more substituents independently selected from halogen, alkyl, haloalkyl, alkyloxy, C_1-C_3 haloalkyloxy or heterocyclyl;

R_2 is H, halogen, deuterium, alkyl, haloalkyl, C_1-C_3 alkyloxy, C_1-C_3 haloalkyloxy,hydroxyalkyl, alkoxyalkyl, cycloalkyl, C_1-C_3 alkylaryl, , substituted or unsubstituted aryl,

substituted or unsubstituted aralkyl, , , or , wherein each R_9 is independently selected from C_1-C_3 alkyl, cycloalkyl or substituted or unsubstituted phenyl;

or R_1 and R_2 together with the carbon atoms to which they are attached form an optionally substituted 5, 6, or 7- membered fused 1,2- carbocyclic ring system with the thiazole ring, wherein the ring carbons of the 5, 6, or 7- membered fused ring are optionally substituted by one or more atoms selected from N, O, and S, and wherein the fused 5, 6, or 7-membered ring is optionally substituted by one or more halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, C_1-C_3 alkyloxy, C_1-C_3 haloalkyloxy, or an optionally substituted aryl ring;

or R_1 and R_2 together with the carbons to which they are attached form substituted or unsubstituted




;

R_3 is hydrogen, C_1-C_3 alkyl, or C_1-C_3 haloalkyl;

each R_4 is independently hydrogen, CD_3, substituted or unsubstituted phenyl, cycloalkyl, C_1-C_3 alkyl, C_1-C_3 haloalkyl, -OR, C_1-C_3 haloalkyloxy, or halogen;

R_5 is hydrogen, C_1-C_3 alkyl, or C_1-C_3 haloalkyl;

R_6 is hydrogen, CD_3, alkyl, cycloalkyl, haloalkyl,



;


each R_7 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, or halogen;

R_8 is hydrogen, alkyl, haloalkyl, cycloalkyl, or halocycloalkyl;

n is 0, 1, or 2; and


p is 0, 1, 2, or 3.


2. The compound according to claim 1, wherein R_1 is:


a) , wherein each R is independently halogen, C_1-C_3 alkyl, C_1-C_3 haloalkyl, or C_3 cycloalkyl; and m is 1, 2, or 3

b) phenyl substituted by two or more substituents independently selected from the group consisting of halogen, alkyl, haloalkyl, 3-F, 4-oxetanephenyl, and C_1-C_3 haloalkyloxy;

c) phenyl substituted by one or more halogen; or






d) .



3. The compound of claim 1 or 2, wherein R_2 is:

a) hydrogen or deuterium;

b) halogen, optionally wherein the halogen is fluorine or chlorine;

c) substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, hydroxyalkyl, or cyclopropyl;

d)  or ; or

e)  or  .

4. The compound of any one of claims 1-3, wherein R_3 is H.

5. The compound of any one of claims 1-4, wherein each R_4 is independently methyl, fluorine, or CF_3.

6. The compound of any one of claims 1-5, wherein R_5 is H.

7. The compound of any one of claims 1-6, wherein R_6 is hydrogen.


8. The compound of any one of claims 1-7, wherein each R_7 is independently hydrogen.

9. The compound of any one of claims 1-8, wherein R_8 is C_1-C_3 alkyl, optionally methyl.


10. The compound of any one of claims 1-9, wherein n is 0 or 1.

11. The compound of any one of claims 1-10, wherein p is 0 or 1.


12. The compound of claim 1, wherein the compound of formula (**I**) has the structure:




,









,





















,













,


HO
O
NH
N
HN
O
S
O
N
S
F
,

F
Cl
N
S
NH
O
S
O
N
HN
OH
O
Me
,

HO
O
NH
N
HN
O
S
O
N
S
,

F
Cl
N
S
NH
O
S
O
N
HN
OH
O
Me
,

HO
O
NH
N
HN
O
S
O
N
S
,

F
Cl
N
S
NH
O
S
O
N
HN
OH
O
Me
,



,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,


,




,




,




,




,




,








,



,



,


,

,

,

,

or ,

or a pharmaceutically acceptable salt thereof.

13. A composition comprising the compound of any one of claims 1-12, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or stereoisomer thereof, and a pharmaceutically acceptable carrier.

14. Use of a compound, or pharmaceutically acceptable salt, prodrug, solvate, hydrate, or stereoisomer thereof of any one of claims 1-12 or a composition of claim 13 in the manufacture of a medicament for treating or preventing a 12-lipoxygenase-mediated disease or disorder.

15. The use of claim 14, wherein the 12-LOX-mediated disease or disorder is selected from the group consisting of skin diseases and platelet hemostasis, transplantation/xenotransplantation, cancer, Type 1 diabetes, Type 2 diabetes,

diabetic kidney disease, diabetic neuropathy, diabetic retinopathy, cardiovascular disease, thrombosis, heparin induced thrombocytopenia (HIT), Alzheimer's disease, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease, insulin resistance, arthritis, lupus (SLE), lupus nephritis, and inflammation, optionally wherein the disease or disorder is HIT.